Chef R, Meert B
J Gynecol Obstet Biol Reprod (Paris). 1978 May-Jun;7(5):1003-12.
After having reviewed our present knowledge of the pharmacology of bromocriptine, its action on the pituitary, centrally and peripherally, the authors detail the results they have obtained in inhibiting lactation in two groups of patients who had delivered normally or had Caesarean sections. In the first group where bromocriptine was started in the first 24 hours with dosages of 2.5 mg every 12 hours for 14 days, clinical signs of breast engorgement and of milk secretion were insignificant and the level of prolactin had dropped to normal menstrual cycle levels from the third day after delivery. In the second group where the first dose of bromocriptine was given at least 48 hours after Caesarean section, the levels of prolactin dropped just as sharply from the third day after delivery, but on the other hand the clinical signs of breast engorgement and milk secretion were marked and completely comparable to those which are found in patients who are not going to breast feed but who have received no treatment to inhibit lactation.
在回顾了我们目前关于溴隐亭药理学的知识，及其对垂体、中枢和外周的作用后，作者详细阐述了他们在两组正常分娩或剖宫产患者中抑制泌乳所取得的结果。在第一组中，在产后24小时内开始使用溴隐亭，剂量为每12小时2.5毫克，持续14天，乳房充盈和乳汁分泌的临床症状不明显，催乳素水平从产后第三天起已降至正常月经周期水平。在第二组中，剖宫产术后至少48小时给予第一剂溴隐亭，催乳素水平从产后第三天起同样急剧下降，但另一方面，乳房充盈和乳汁分泌的临床症状明显，与那些不打算母乳喂养但未接受抑制泌乳治疗的患者的症状完全相当。
